U.K.-based SkyePharma's Flutiform, an inhaled combination of fluticasone and formoterol, has been launched in Germany by the company's partner, Mundipharma, as an asthma maintenance therapy.

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...

Respiratory player Vectura can set aside its hopes of snagging a new COPD indication for its combination med Flutiform--at least for now. Tuesday, the U.K. company said that its ICS/LABA med had ...

LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE: SKP) today provides an update following a meeting held with the US Food and Drug Administration (FDA) to discuss the previously announced potential ...

LONDON (MarketWatch) -- U.K. drug delivery company SkyePharma PLC Tuesday said it has signed a deal with Kyorin Co. Ltd. (4569.TO) to develop and distribute its key experimental product, asthma ...

(Reuters) - British drugmaker Vectura said its asthma inhaler Flutiform had made favorable regulatory progress in Europe, and it can now apply for approvals through its partner. Vectura said its ...

Regulatory filing in Europe is expected during the first quarter of 2010. SkyePharma and Mundipharma have reported positive results from a Phase III trial with the inhaled asthma drug combination, ...

Vectura said today that its marketed asthma drug flutiform ® has failed a Phase III trial intended to support an additional indication in Europe of chronic obstructive pulmonary disease (COPD).

(Reuters) - Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD, a type of lung disease, sending ...

SkyePharma’s shares were given a hefty boost yesterday after the company announced that a late-stage trial of Flutiform was a success, paving the way for the drug’s filing in Europe during the first ...